middle.news
How Is ImpediMed Capitalising on $3.9M Revenue and US Heart Health Launch?
8:34am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
How Is ImpediMed Capitalising on $3.9M Revenue and US Heart Health Launch?
8:34am on Thursday 29th of January, 2026 AEDT
Key Points
Q2 FY26 revenue reaches $3.9 million, up 8% quarter-on-quarter
Annual Recurring Revenue steady at $14.4 million
Breast Cancer Related Lymphoedema (BCRL) reimbursement coverage expands to 93% nationally
US Heart Health commercial activities commence leveraging SOZO Pro platform
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMPEDIMED (ASX:IPD)
OPEN ARTICLE